Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance

Elettra Fallani, MSc1, Fabio Cevenini, MSc2, Pietro Enea Lazzerini, MD3, Annalisa Verdini, MSc4, and Simona Saponara, PhD1

Abstract
This study aimed to characterize adverse drug reactions (ADRs) to hydroxychloroquine in the setting of COVID-19, occurring in Italy in the period March to May 2020. The analysis of the combination therapy with azithromycin or/and lopinavir/ritonavir as well as a comparison with ADRs reported throughout 2019 was performed. ADRs collected by the Italian National Network of Pharmacovigilance were analyzed for their incidence, seriousness, outcome, coadministered drugs, and Medical Dictionary for Regulatory Activities classification. A total of 306 reports were gathered for the quarter of 2020: 54% nonserious and 46% serious, and half of the latter required either the hospitalization or its prolongation. However, most of them were either completely recovered (26%) or in the process of recovery (45%), except for 9 fatal cases. Throughout 2019, 38 reports were collected, 53% nonserious and 47% serious, but no deaths had been reported. Diarrhea, prolonged QT interval, and hypertransaminasemia were the most frequently ADRs reported in 2020, significantly higher than 2019 and specific for COVID-19 subjects treated with hydroxychloroquine. The logistic regression analyses demonstrated that the likelihood of serious ADRs, QT prolongation, and diarrhea significantly increased with hydroxychloroquine dosage. Coadministration of lopinavir/ritonavir and hydroxychloroquine showed a positive correlation with diarrhea and hypertransaminasemia and a negative relationship with the ADR seriousness. The combination therapy with azithromycin was another independent predictor of a serious ADR. Off-label use of hydroxychloroquine for COVID-19, alone or in combination regimens, was associated with increased incidence and/or seriousness of specific ADRs in patients with additional risk factors caused by the infection.

Keywords
adverse drug reactions, azithromycin, COVID-19, hydroxychloroquine, lopinavir/ritonavir

Hydroxychloroquine (HCQ) is an antimalarial agent, currently used for the treatment of autoimmune diseases, such as rheumatoid arthritis1 and systemic lupus erythematosus.2 HCQ was one of the first drugs “off-label” repurposed for the prevention and the therapeutic management of COVID-19, as in vitro data demonstrated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero E6 cells.3,4

Due to its weak basic properties, HCQ accumulates within acidic vesicles, such as lysosomes and endosomes,5 increasing their pH and preventing endocytosis, exosome release, and phagolysosomal fusion.6 Moreover, like its structural analog chloroquine, it can impair the SARS-CoV-2 attachment and entry in the host cell through the inhibition of the N-glycosylation of the cell surface viral receptor ACE2.7,8 and it may additionally prevent SARS-CoV-2 from binding with gangliosides.9 Besides its antiviral activity, HCQ modulates innate and adaptive immune cell activation, cytokine response, and inflammation.5,8

Based on these findings, the negligible cost, the ease of administration and the known safety profile of HCQ within the approved indications, a considerable number of clinical trials have been launched to evaluate its effectiveness against COVID-19. The results obtained so far are controversial, and a number of potential biases and confounding factors limit their robustness.

Early clinical studies conducted in China10 and in France11,12 suggested that HCQ use was associated with a short time to clinical recovery and to viral load.

---

1Dipartimento di Scienze della Vita, Università di Siena, Siena, Italy
2Dipartimento di Economia e Management, Università di Trento, Trento, Italy
3Dipartimento di Medicina, Chirurgia e Neuroscienze, Università di Siena, Siena, Italy
4Dipartimento del Farmaco, Azienda USL Toscana Sud Est, Siena, Italy

Submitted for publication 15 August 2021; accepted 16 November 2021.

Corresponding Author:
Simona Saponara, PhD, Dipartimento di Scienze della Vita, Università di Siena, via Aldo Moro, 2, Siena, Italy
Email: simona.saponara@unisi.it
reduction/disappearance in patients with COVID-19, and its effect is reinforced by azithromycin.

On the basis of these preliminary results, HCQ has been prescribed worldwide.

Several retrospective observational studies\textsuperscript{13–16} suggested that treatment with either HCQ alone or in combination with azithromycin is associated with reduction in COVID-19 mortality, better clinical outcome, and more rapid virus clearance when compared to other treatments.

Conversely, 3 multicenter, randomized controlled trials\textsuperscript{17–19} and some large observational studies\textsuperscript{20–23} found a nonsignificant association between HCQ administration and clinical end points like intubation or death in hospital mortality.

The widespread use of HCQ began to dwindle after the publication of a multinational registry analysis\textsuperscript{24} demonstrating an increased risk of in-hospital mortality and ventricular arrhythmia associated with the use of HCQ with or without a macrolide, then retracted due to the nonguarantee of the veracity of the primary data sources.\textsuperscript{25}

Afterwards, the multicenter RECOVERY,\textsuperscript{26} ORCHID,\textsuperscript{27} and Solidarity\textsuperscript{28} trials halted enrollment of patients with COVID-19 in the HCQ arm based on interim analysis showing no evidence of benefit or harm.

Serious concerns have been raised regarding HCQ safety use in the setting of SARS-Cov-2 disease, particularly QT prolongation and arrhythmias,\textsuperscript{29,30} and several observational studies were published on the potentially arrhythmogenic effect of HCQ and its combination with azithromycin.\textsuperscript{31–36} Both drugs are associated with known risk of torsade de pointes (TdP), even when taken as recommended.\textsuperscript{37}

Furthermore, patients with COVID-19 are likely to have higher arrhythmic risks as a result of the metabolic and physiologic changes due to their illness and co-morbidities, including myocardial injury, high-grade systemic inflammatory state, electrolyte imbalances, and concomitant QT-prolonging medications.\textsuperscript{38–40}

Thus, the European Medicines Agency and Italian Medicines Agency established that HCQ should only be used in clinical trials for the treatment of COVID-19.\textsuperscript{41,42}

Therefore, the aim of this study was a retrospective analysis of suspected adverse drug reaction (ADR) reports to HCQ, collected by the Italian National Network of Pharmacovigilance (NPP), between March 1, 2020, and May 31, 2020, the period of the first wave of COVID-19 in Italy.

**Materials and Methods**

The Italian NPP was queried for suspected ADRs associated with HCQ that occurred in Italy in the period March 1, 2020, to May 31, 2020, the first wave of the pandemic. Downloaded reports were compared to those collected throughout the year 2019 and, for each of them, age, sex, seriousness, outcomes, concomitant medications, source, and type of reporting were gathered.

Seriousness and outcomes have been classified according to the Eudravigilance criteria. A suspected adverse reaction was listed as serious if it resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, or resulted in a congenital anomaly/birth defect. The outcome, providing information on the last reported status of the suspected undesirable effect, was classified as resolved, resolving, resolved with sequelae, not resolved, fatal, or not specified.

ADRs were classified by group queries according to the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term (PT) and System Organ Class (SOC)\textsuperscript{43} and their seriousness and outcomes classified according to the Eudravigilance criteria.

Drugs used were listed according to the World Health Organization’s Anatomical Therapeutic Chemical classification system.\textsuperscript{44}

Analysis of the data were accomplished using Prism version 5.04 (GraphPad Software Inc., San Diego, California) and the open-source statistical software R, version 8.16 (R Foundation for Statistical Computing, Vienna, Austria).

Descriptive statistics were used to summarize data, expressed as mean ± standard error or frequency with percentage, where appropriate. The statistical association between variables was assessed using Fisher’s exact test, as applicable.

Multivariate logistic regression analysis, based on the maximum likelihood ratio criterion,\textsuperscript{45} was performed to identify which risk factors (independent variables) could have affected the likelihood of a serious ADR, QT prolongation, diarrhea, and hypertransaminasemia (dependent variables). Additionally, the impact of HCQ dosage on the dependent variables was explored while controlling for those independent variables that had shown a significant relationship in the previous models.

A value of $P < .05$ was considered significant.
### Results

#### March to May 2020 Reports

Within the period March to May 2020, 306 reports featuring at least 1 ADR associated with HCQ were collected. Characteristics of reporters, patients, and HCQ daily dosage are shown in Tables S1, S2, and S3, respectively.

Of 306 reports, 54.2% were defined as nonserious and 45.8% serious; of the latter, 49.3% required either inpatient hospitalization or the prolongation of existing hospitalization, 41.4% were represented by other medically important conditions, and 2.9% by life-threatening reactions (Table 1). Nine cases of death were observed: 2 of unknown cause, 5 not due to HCQ, and 2 possibly related to HCQ use/associated with HCQ use. No report resulted in persistent or significant disability/incapacity or in a congenital anomaly/birth defect (Table 1). The patient’s age did not affect the seriousness (mean age: nonserious reports, 63 ± 1.2 years; serious reports, 65 ± 1.4 years).

Regardless of the seriousness, 25.8% of patients were completely recovered, 45.4% in the process of recovery, 5.9% nonrecovered, and 1% recovered with sequelae at the time of reporting. The outcome was not available in 19% of reports and was fatal in 9 cases (Table 1).

A total of 506 MedDRA PTs, corresponding to 23 different SOCs were identified (Table 2). The most frequently reported ADRs were diarrhea, corrected QT interval (QTc) prolongation, and hypertransaminasemia (Table 3).

The 306 reports also included those of 11 patients who did not have COVID-19 who took HCQ for autoimmune diseases. None of the 3 ADRs, previously reported, were detected in these reports (Table 3).

Overall, 21% of all PTs associated with off-label use of HCQ were represented by cardiovascular ADRs (Table S4).

In 223 reports, HCQ was coded as suspected and in 83 as concomitant.

Polypharmacy (use of >5 drugs) was detected in 83 reports, 42 nonserious and 41 serious, including 8 deaths. Overall, 1044 drugs, consisting of 217 different medicinal products, were coadministered with HCQ (Tables S5 and S6). Of these coadministered medicines, 46 are broken into 4 categories that represent different levels of certainty, by Crediblemeds.org, the most reliable, up-to-date resource of drugs classified by their potential to cause QT prolongation and/or TdP46 (Table S7). In 42 of the 54 cases of long QT,
### Table 2. Distribution of ADRs That Occurred With HCQ Administration During March to May 2020 and January to December 2019 According to MedDra SOC Classification

| MedDra SOC                                      | Number of Reported Reactions (MedDra PT) | March to May 2020 | January to December 2019 |
|------------------------------------------------|----------------------------------------|-------------------|--------------------------|
| Blood and lymphatic system disorders             | 26                                     |                   | 3                        |
| Cardiac disorders                               | 37                                     |                   | 3                        |
| Congenital, familial, and genetic disorders     | 1                                      |                   | 2                        |
| Ear and labyrinth disorders                    | 1                                      |                   | 1                        |
| Endocrine disorders                             | 1                                      |                   | 1                        |
| Eye disorders                                   | 2                                      |                   | 2                        |
| Gastrointestinal disorders                      | 87                                     |                   | 6                        |
| General disorders and administration site conditions | 26                               |                   | 11                       |
| Hepatobiliary disorders                         | 24                                     |                   | 2                        |
| Immune system disorders                         | 5                                      |                   | 4                        |
| Infections and infestations                     | 18                                     |                   | 4                        |
| Injury, poisoning, and procedural complications  | 6                                      |                   | 1                        |
| Investigations                                  | 107                                    |                   | 4                        |
| Metabolism and nutrition disorders              | 18                                     |                   | 2                        |
| Musculoskeletal and connective tissue disorders | 4                                      |                   | 7                        |
| Nervous system disorders                        | 16                                     |                   | 4                        |
| Psychiatric disorders                           | 6                                      |                   | 4                        |
| Renal and urinary disorders                     | 2                                      |                   | 1                        |
| Reproductive system and breast disorders        | 1                                      |                   | 1                        |
| Respiratory, thoracic, and mediastinal disorders| 17                                     |                   | 2                        |
| Skin and subcutaneous tissue disorders          | 95                                     |                   | 18                       |
| Social circumstances                            | 1                                      |                   | 1                        |
| Vascular disorders                              | 5                                      |                   | 2                        |

ADRs, adverse drug reactions; HCQ, hydroxychloroquine; MedDRA, Medical Dictionary for Regulatory Activities; PT, Preferred Term; SOC, System Organ Class.

### Table 3. Most Frequent PTs Reported in 2020 (March to May) and Comparison With Corresponding Frequencies in 2019 (January to December)

| PT                                      | 2020, n (%) | 2019, n (%) | P     | 2020 No COVID, n (%) |
|-----------------------------------------|-------------|-------------|-------|----------------------|
| Diarrhea                                | 58/506 (11%)| 0/72        | .0005 | 0/23                 |
| Electrocardiogram prolonged QT/LQTS     | 54/506 (11%)| 0/72        | .0008 | 0/23                 |
| Hypertransaminasemia/ increased transaminase/increased ALT/ increased AST | 45/506 (9%) | 0/72 | .0036 | 0/23 |
| Erythema                                | 14/506 (3%) | 3/72 (4%)   | .45   | 2/23 (9)             |
| Bradycardia/conduction disorders        | 13/506 (3%) | 0/72        | .38   | 0/23                 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; LQTS, long QT syndrome; PTs, Preferred Terms

Differences between column 2020 and 2019 were evaluated by the Fisher exact test.

HCQ was associated with at least 1 other drug listed by Crediblemeds.

According to the Liverpool Drug Interactions website47 providing information on the likelihood of interactions between HCQ and commonly prescribed comedications, 506 potential drug-drug interactions between HCQ and 77 different medicinal products have been found.

### Adverse Drug Reactions Associated With a Combination of HCQ and Lopinavir/Ritonavir and/or Azithromycin

A deeper analysis of the ADRs associated with the coadministration of HCQ and lopinavir/ritonavir and/or azithromycin, the 2 most frequently prescribed comedications, was performed.

Among the reports, 131 (71% nonserious, 29% serious) included the combination HCQ plus lopinavir/ritonavir, 72 (33% nonserious, 67% serious) HCQ plus azithromycin, and 32 (56% nonserious, 44% serious) the triple therapy with HCQ plus lopinavir/ritonavir and azithromycin (Table 4). Most ADRs have been resolved or are in the process of being resolved, although 3 deaths were observed in the HCQ plus azithromycin group, which is the treatment regimen with the highest reporting seriousness (Table 4).

Indeed, the logistic regression analyses showed that the likelihood of serious ADRs significantly increased or decreased with coadministration of azithromycin and lopinavir/ritonavir, respectively (Table 5). Additionally, controlling for these 2 independent
Table 4. Outcomes of Nonserious and Serious Reports of Patients Treated With Several Combination Therapies (March to May 2020)

**Hydroxychloroquine Plus Lopinavir/Ritonavir**

| Outcome                  | Nonserious (n = 93) | Serious (n = 38) |
|--------------------------|--------------------|-----------------|
| Resolved                 | 13                 | 9               |
| Resolving                | 55                 | 22              |
| Resolved with sequelae   | 0                  | 0               |
| Not resolved             | 1                  | 2               |
| Not specified            | 24                 | 4               |
| Fatal                    | 0                  | 1              |

**Hydroxychloroquine Plus Azithromycin**

| Outcome                  | Nonserious (n = 24) | Serious (n = 48) |
|--------------------------|--------------------|-----------------|
| Resolved                 | 1                  | 15              |
| Resolving                | 14                 | 21              |
| Resolved with sequelae   | 0                  | 0               |
| Not resolved             | 0                  | 4               |
| Not specified            | 9                  | 5               |
| Fatal                    | 0                  | 3              |

**Hydroxychloroquine Plus Lopinavir/Ritonavir and Azithromycin**

| Outcome                  | Nonserious (n = 18) | Serious (n = 14) |
|--------------------------|--------------------|-----------------|
| Resolved                 | 1                  | 3               |
| Resolving                | 10                 | 9               |
| Resolved with sequelae   | 0                  | 0               |
| Not resolved             | 0                  | 0               |
| Not specified            | 7                  | 1               |
| Fatal                    | 0                  | 1              |

*One drug could have contributed.

**Discussion**

This study demonstrates that in Italy during the first wave of pandemic, off-label use of HCQ in patients with COVID-19 was associated with higher reporting compared to the whole previous year. Diarrhea, QT prolongation, and hypertransaminasemia were the most frequently reported ADRs, specifically in subjects assuming HCQ for the treatment of COVID-19, in agreement with most frequent reported ADRs identified by Zekarias et al through the analysis of 2573 reports on COVID-19–specific treatments from VigiBase, the World Health Organization’s global ADR database.

Although there was no difference in patients’ mean age, in the 2 periods studied, a sex difference was identified. In line with literature, in a COVID-19 setting, ADRs were reported more frequently in men, consistent with the higher risk of severe disease and death in men than in women but during HCQ label use, more frequently in women, in agreement with female predominance of autoimmune diseases.

The percentage of serious and nonserious reports in the 2 periods analyzed was comparable, and no differences in outcomes were appreciated, except for pandemic ADRs that resolved with sequelae or were fatal.

Multivariate logistic regression analyses showed that, during 2020, unlike age and sex of patients, the HCQ dose and the coadministration of azithromycin were significantly associated with the seriousness of the
### Table 5. Multivariate Logistic Regression Analysis

| Dependent Variable | Variable          | Regression Coefficient | Standard Error | P Value   | Significance |
|--------------------|-------------------|------------------------|----------------|-----------|-------------|
| Seriousness<sup>a</sup> | Intercept         | -0.706750              | 0.528787       | .181      |             |
|                    | Azithromycin      | 1.347767               | 0.311793       | 1.54e-<sup>05</sup> | ***        |
|                    | Lopinavir/ritonavir | -1.254224              | 0.260452       | 1.47e-<sup>06</sup> | ***        |
|                    | Sex<sup>c</sup>   | -0.073800              | 0.253928       | .771      |             |
|                    | Age               | 0.012571               | 0.007896       | .111      |             |
| Seriousness<sup>b</sup> | Intercept         | -1.540681              | 0.500124       | .00207    | **          |
|                    | HCQ dosage        | 0.003995               | 0.001299       | .00209    | **          |
|                    | Azithromycin      | 1.26824                | 0.322042       | 8.21e-<sup>05</sup> | ***        |
|                    | Lopinavir/ritonavir | -1.270305              | 0.285786       | 8.79e-<sup>06</sup> | ***        |
| Prolonged QT<sup>a</sup> | Intercept         | -8.74928               | 1.31340        | 2.71e-<sup>11</sup> | ***        |
|                    | Azithromycin      | -0.18760               | 0.42762        | .661      |             |
|                    | Lopinavir/ritonavir | 0.18544                | 0.35092        | .597      |             |
|                    | Sex<sup>c</sup>   | -0.36352               | 0.34720        | .293      |             |
|                    | Age               | 0.10390                | 0.01688        | 7.50e-<sup>10</sup> | ***        |
| QT prolonged<sup>b</sup> | Intercept         | -9.2182448             | 1.461614       | 2.85e-<sup>10</sup> | ***        |
|                    | HCQ dosage        | 0.00334                | 0.001587       | .0353     | *           |
|                    | Age               | 0.092247               | 0.016877       | 4.60e-<sup>08</sup> | ***        |
| Diarrhea<sup>a</sup>    | Intercept         | -0.27223               | 0.63930        | .6703     |             |
|                    | Azithromycin      | -0.31381               | 0.38122        | .41041    |             |
|                    | Lopinavir/ritonavir | 1.47118                | 0.32859        | 7.36e-<sup>06</sup> | ***        |
|                    | Sex<sup>c</sup>   | 0.34742                | 0.31981        | .27733    |             |
|                    | Age               | -0.03351               | 0.01024        | .00106    | **          |
| Diarrhea<sup>b</sup>    | Intercept         | -1.941341              | 0.889942       | .02915    | *           |
|                    | HCQ dosage        | 0.004884               | 0.001663       | .00331    | **          |
|                    | Age               | -0.037551              | 0.011453       | .00104    | **          |
|                    | Lopinavir/ritonavir | 1.807102               | 0.381181       | 2.13e-<sup>06</sup> | ***        |
| Hypertransaminasemia<sup>a</sup> | Intercept         | -2.16534               | 0.77305        | .00509    | **          |
|                    | Azithromycin      | 0.44291                | 0.37742        | .24058    |             |
|                    | Lopinavir/ritonavir | 1.02188                | 0.35029        | .00353    | **          |
|                    | Sex<sup>c</sup>   | 0.61502                | 0.36424        | .09131    |             |
|                    | Age               | -0.01070               | 0.01109        | .33452    |             |
| Hypertransaminasemia<sup>b</sup> | Intercept         | -1.371695              | 0.613908       | .0255     | *           |
|                    | HCQ dosage        | -0.002312              | 0.001635       | .1573     |             |
|                    | Lopinavir/ritonavir | 0.911559               | 0.361229       | .0116     | *           |

HQC, hydroxychloroquine.

<sup>a</sup>A total of 306 observations.

<sup>b</sup>A total of 259 observations (HCQ dosage was missing in 47 reports; see Table S3).

<sup>c</sup>Sex was codified as a dummy equal to 1 in case of male, 0 instead.

* P < .05, ** P < .01, *** P < .001.

According to MedDRA hierarchy, during a COVID-19 scenario, most ADRs belonged to SOC “investigations,” followed by “skin and subcutaneous disorders” and “gastrointestinal disorders,” whereas during the pre-COVID-19 period, the 3 most common symptom manifestations were dermatologic conditions, general disorder, and administration site conditions as well as musculoskeletal and connective disorders. In COVID-19 reports, half of the “investigations” were represented by the ECG prolonged QT, in addition to ECG repolarization abnormalities, long QT syndromes, ventricular...
tachycardia, and bradycardia, which also occurred, all predisposing to TdP. It is noteworthy that no case of TdP was reported. Several studies demonstrated that the incidence of malignant life-threatening tachyarrhythmia is extremely low in a short period of either HCQ or HCQ plus azithromycin administration.\textsuperscript{31–36} Conversely, no case of long QT was reported throughout 2019. Remarkably, the 306 reports from the COVID-19 era also included those of 11 patients without COVID-19 taking HCQ, as approved for autoimmune diseases. QT prolongation and more in general cardiovascular ADRs were not detected in any of these reports. HCQ was also associated with bradycardia/conduction disorders, although the incidence was lower and not significantly different when compared to 2019.

In patients with SARS-CoV-2, the 2 most frequently coadministered drugs with either possible or known risk of inducing long QT/TdP were lopinavir/ritonavir and azithromycin, respectively.

Several studies have shown that the combination of HCQ and azithromycin was associated with a greater increase in QT interval in patients with COVID-19\textsuperscript{32,33} as well as with more serious cardiovascular ADRs in patients rheumatic disorders\textsuperscript{58} when compared with monotherapy. Moreover, a recent prospective observational study demonstrated that patients treated with either HCQ plus azithromycin or HCQ plus azithromycin and lopinavir/ritonavir had prolonged QTc compared to baseline values, but patients with triple therapy did not show a greater increase in the QTc than those on double therapy.\textsuperscript{59}

In our analysis, neither azithromycin nor lopinavir/ritonavir coadministration seemed to be associated with prolonged QT, but only the age of patients and the HCQ dose, in agreement with Bernardini et al\textsuperscript{60} and Juurlink.\textsuperscript{61}

Besides concomitant therapies, COVID-19 per se might be an important factor enhancing the risk of adverse reactions to HCQ. In fact, it is increasingly recognized that, in COVID-19, myocardial involvement is common, possibly due to multiple mechanisms including direct viral infection, hypoxia-induced apoptosis, and cytokine storm–related cell damage.\textsuperscript{38,39} Moreover, regardless of the development of cardiac injury, inflammatory cytokines can also exert direct electrophysiological effects on the myocardium, promoting QTc prolongation.\textsuperscript{62–64} In particular, it has been demonstrated that interleukin-6, which is commonly found at high levels in patients with COVID, directly inhibits the ether-à-go-go–related gene potassium channel channels and prolongs action potential duration in ventricular myocytes.\textsuperscript{65}

These mechanisms may contribute to explain the high incidence of QTc prolongation that we observed in 2020, specifically in patients assuming HCQ for COVID-19.

Disease-specific considerations could also account for gastrointestinal and hepatic adverse reactions, similarly reported to an increased extent in 2020 in patients with COVID-19. Indeed, a recent pooled analysis of the available clinical data revealed an overall diarrhea rate of about 10% in patients with COVID-19,\textsuperscript{66} a percentage overlapping that we observed in our HCQ-treated patients with COVID-19 in 2020, but significantly higher when compared to a previous study on HCQ in rheumatoid arthritis.\textsuperscript{49}

Similarly, a large retrospective observational cohort study demonstrated that hypertransaminasemia is relatively common during active COVID-19,\textsuperscript{67} while it was reported in <1% of patients with rheumatoid arthritis administered HCQ.\textsuperscript{68}

However, regression logistic analyses revealed that age and coadministration of lopinavir/ritonavir showed a positive correlation with diarrhea and hypertransaminasemia, as recently reported by Giacomelli et al.\textsuperscript{69} Moreover, the age of patients and the dose of HCQ were found to decrease and increase the likelihood of diarrhea, respectively, in agreement with Unim et al\textsuperscript{70} and Munster et al.\textsuperscript{54}

### Conclusions

This study suggests that off-label use of HCQ for COVID-19, alone or in combination with lopinavir/ritonavir and/or azithromycin, was associated with an increased incidence and/or seriousness of specific ADRs, in patients with additional risk factors including the infection itself, notwithstanding biases and limitations of the pharmacovigilance analysis.

Indeed, though the spontaneous ADR reporting system represents the mainstay of pharmacovigilance, allowing the early detection of possible safety signals and the continuous monitoring and evaluation of potential safety issues, it suffers from several limitations and biases imbedded in the concept of voluntary reporting.\textsuperscript{71} Shortcomings include multiplicity of reporters; retrospective and open collection of data, generating missing information, and thus potential uncertainties and distortions; underreporting or overreporting; absence of either naïve control patients or patients receiving the drug without ADRs, incompleteness of reports due to lack of exposure data and comorbidities.

Though these findings deserve further investigations and validation, they have important implications that impose caution in HCQ indication, especially for
patients susceptible to cardiovascular as well as intestinal and hepatic toxicities.

Acknowledgments

The authors acknowledge the networking contribution by the COST Action STRATAGEM, CA17104, supported by the European Cooperation in Science and Technology (www.cost.eu).

Conflicts of Interest

The authors declare no conflicts of interest.

Funding

No funding was obtained for the preparation of this article.

Author Contributions

E.F., P.E.L., and S.S. wrote the article; A.V. and S.S. came up with the study concept; E.F., A.V., and S.S. designed the research; E.F., F.C., and S.S. performed the research; E.F., F.C., P.E.L., and S.S. performed the data analyses.

References

1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-699.
2. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
3. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
4. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-739.
5. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166.
6. Tripathy S, Dassarma B, Roy S, Chabala H, Matsabisa MG. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SARS-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56(2):106028.
7. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virul J. 2005;2:69.
8. Quiros Roldan E, Biasiottio G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against SARS-CoV-2 infection (COVID-19): a role for iron homeostasis? Pharmacol Res. 2020;158:104904.
9. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960.
10. Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;63(10):1515-1521.
11. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
12. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.
13. Arshad S, Kilgore P, Chaudhry ZS, et al. Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.
14. COVID-19 RISK and Treatments (CORIST) Collaboration. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med. 2020;82:38-47.
15. Lagier JC, Million M, Gautret P, et al. IHU COVID-19 Task force. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.
16. Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738.
17. Cavalcani AB, Zampieri FG, Rosa RG, et al. Coalition Covid-19 Brazil I investigators. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041-2052.
18. Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(21):2165-2176.
19. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
20. Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
21. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine and azithromycin on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. Int J Antimicrob Agents. 2020;158:104904.
22. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin in hospitalised COVID-19 patients with hydroxychloroquine and azithromycin usage in United States veterans hospitalized with COVID-19. Med (N Y). 2020;1(1):114-127.
23. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493-2502.
24. Geleris J, Sun Y, Plott J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411-2418.
25. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Retraction: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.
26. Mehra MR, Ruschitzka F, Patel AN. Retraction - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820.
27. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020.
28. Casey JD, Johnson NJ, Semler MW, et al. Rationale and design of ORCHID: a randomized placebo-controlled clinical trial of...
hydroxychloroquine for adults hospitalized with COVID-19. *Ann Am Thorac Soc*. 2020;17(9):1144-1153.

28. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. *N Engl J Med*. 2021;384(6):497-511.

29. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). *Mayo Clin Proc*. 2020;95(6):1213-1221.

30. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. *J Am Coll Cardiol*. 2020;75(20):2623-2624.

31. Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. *JAMA Cardiol*. 2020;5(9):1036-1041.

32. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients tested positive for coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(9):1047-1049.

33. Saleh M, Gabriels J, Chang D, et al. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. *Circ Arrhythm Electrophysiol*. 2020;13(6):e008662.

34. Saleh M, Gabriels J, Chang D, et al. Northwell COVID-19 research consortium. Safely administering potential QTc prolonging therapy across a large health care system in the COVID-19 era. *Circ Arrhythm Electrophysiol*. 2020;13(11):e009397.

35. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. *Nat Med*. 2020;26(6):808-809.

36. Chorin E, Wadhwa L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. *Heart Rhythm*. 2020;17(9):1425-1433.

37. Woosley RL, Heise CW, Gallo T, et al. QTdrugs list. https://www.crediblemeds.org/. Accessed October 31, 2021.

38. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. *J Am Coll Cardiol*. 2020;75:2352-2371.

39. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19: arrhythmic risk, and inflammation: mind the gap. *Circulation*. 2020;142(1):7-9.

40. Turagam MK, Musikanot D, Goldman ME, et al. Malignant arrhythmias in patients with COVID-19: incidence, mechanisms, and outcomes. *Circ Arrhythm Electrophysiol*. 2020;13(11):e009820.

41. European Medicines Agency. COVID-19: reminder of the risks of chloroquine and hydroxychloroquine. https://www.ema.europa.eu/. Accessed October 30, 2021.

42. Italian Medicines Agency. COVID-19: AIFA limits the use of remdesivir in selected cases and allows for hydroxychloroquine to be used only in randomised clinical trials in an outpatient setting. https://www.aifa.gov.it/. Accessed October 30, 2021.

43. Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activity. https://www.meddra.org/. Accessed October 20, 2021.

44. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. 2021. https://www.whocc.no/atc_ddd_index/. Accessed August 14, 2021.
63. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. *Nat Rev Immunol*. 2019;19(1):63-64.

64. Rubin GA, Desai AD, Chai Z, et al. Cardiac corrected QT interval changes among patients treated for COVID-19 infection during the early phase of the pandemic. *JAMA Netw Open*. 2021;4(4):e216842.

65. Aromolaran AS, Srivastava U, Ali A, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. *PLoS One*. 2018;13(12):e0208321.

66. D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management. *Clin Gastroenterol Hepatol*. 2020;18(8):1663-1672.

67. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a major U.S. hospital network. *Hepatology*. 2020;72(4):1169-1176.

68. van Jaarsveld CH, Jahangier ZN, Jacobs JW, et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. *Rheumatology (Oxford)*. 2000;39(12):1374-1382.

69. Giacomelli A, Pagani G, Ridolfi AL, et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. *J Med Virol*. 2021;93(3):1421-1427.

70. Unim B, Palmieri L, Lo Noce C, Brusaferro S, Onder G. Prevalence of COVID-19-related symptoms by age group. *Aging Clin Exp Res*. 2021;33(4):1145-1147.

71. Council for International Organizations of Medical Sciences. *Practical Aspects of Signal Detection in Pharmacovigilance*: Report of CIOMS Working Group VIII. 2010.1–143.

**Supplemental Information**

Additional supplemental information can be found by clicking the Supplements link in the PDF toolbar or the Supplemental Information section at the end of web-based version of this article.